Transcript
Hi everyone. My name is Viviana Perez. I am a nurse practitioner at Moffitt Cancer Center, specializing in malignant hematology specifically seeing patients with NHL, HL, and CLL. The first abstract that I will be discussing: Real world baseline characteristics and preliminary outcomes in patients with momelotinib in the US community oncology practice setting. Patients with MF suffer from thrombocytopenia, anemia, splenomegaly and other constitutional symptoms. Treatment with JAK inhibitors have had positive effects on spleen size and symptom burden. However, JAK inhibitors may exacerbate anemia. Momelotinib, which is a JAK1/JAK2/ACVR1 inhibitor is the first and only treatment indicated for patients with immediate or high risk MF and anemia. Momelotinib can be prescribed for both JAK inhibitor naïve or patients with prior exposure to JAK inhibitors. In this large study, they included adult patients >18 years old with either primary or secondary MF who received treatment with momelotinib over 8 months. Anemia was classified as a hemoglobin level of less than 10 g/dL. Improvement of hemoglobin was measured in 3 month intervals. Median age at anemia diagnosis was 72 years old. Most patients initiated treatment with momelotinib at 200 mg daily, which is the full dose. The majority of patients in this study (76.9%) had hemoglobin levels between 8-10 g/dL. It was discovered that hemoglobin levels improved by 1 g/dL and that platelet counts also improved. Treating anemia which is exacerbated by MF with momelotinib seems very promising, especially since this drug works for patients that have been exposed to JAK inhibitors and JAK inhibitor naïve patients. It is particularly encouraging to have a medication on the market that noy only targets MF, but also may effectively manage anemia in this pt population. This is also exciting for the patient, as this may require fewer blood transfusions, which means less time in clinic and more time at home!
